Phospholipase A2 Receptor, Monitoring, Enzyme-Linked Immunosorbent Assay, Serum
Use
This test is useful for distinguishing primary from secondary membranous nephropathy and monitoring patients with membranous nephropathy over time for trends in anti-phospholipase A2 receptor antibody levels. Anti-PLA2R antibodies are highly specific for diagnosing primary membranous nephropathy, and their levels can correlate with disease activity and progression.
Special Instructions
This test is available for order by NY State clients. It is recommended to use this test in conjunction with other clinical information. Specimen collection involves centrifuging and aliquoting serum into a plastic vial.
Limitations
This test should not be used as a standalone test but an adjunct to other clinical information. Absence of circulating anti-phospholipase A2 receptor autoantibodies does not rule out a diagnosis of primary membranous nephropathy. A diagnosis should not be made based on a single test result.
FDA ApprovedNew York Approved
Methodology
Immunoassay (ELISA)
Biomarkers
LOINC Codes
- 73737-9
- 73737-9
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
1 mL
Minimum Volume
0.5 mL
Container
Plastic vial
Collection Instructions
Centrifuge and aliquot serum into plastic vial
Causes for Rejection
Gross hemolysis
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 hours |
| Refrigerated | 14 days |
| Frozen | 14 days |